Intercure Ltd. (INCR)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $5.03
- As of
Kresmion compiles this page from INCR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Intercure Ltd. (INCR): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-08.
See the full INCR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INCR on one page. Preview it with sample data, then open it live with a free account.
Preview the INCR dossierActive signals for INCR
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +63% to INCR (2026Q2)
- mediumEARNINGS_MISS
Q3-2022: Missed consensus by 37.3% - EPS $0.16 vs $0.255 estimate
- mediumEARNINGS_MISS
Missed consensus by 37.3% - EPS $0.16 vs $0.255 estimate
- lowEARNINGS_MISS
Q1-2023: EPS $0.005 vs $0.0408 estimate, -0.04 on a near-zero consensus
- mediumEARNINGS_BEAT
Q2-2023: Beat consensus by 28.7% - EPS $0.105 vs $0.0816 estimate
FREE, NO ACCOUNT
Every signal on INCR, as it fires
New filings, 13F moves and cross asset signals on INCR land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in INCR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP M549GJ111 · 2026Q2 | $119K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP M549GJ111 · 2026Q2 | $64K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INCR
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
INCR against its peers
INCR's return on equity of -18.3% ranks in the 25th percentile of 5 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-09-30 and 2024-12-31.
| Metric | INCR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 239M ILS | n/a | n/a | 0 |
| Revenue YoY | -32.8% | n/a | n/a | 1 |
| Gross margin | 12.7% | n/a | n/a | 4 |
| Operating margin | -28.1% | n/a | n/a | 4 |
| Net margin | -30.5% | n/a | n/a | 4 |
| Return on equity | -18.3% | -3.4% | 25 | 5 |
Peers (5): ZYBT, BGM, OGI, CRDL, INIS. Left out: JUSHF (period gap), AAWH (period gap), CWBHF (period gap), CTOR (no annual filing), GRUSF (period gap), CPIX (period gap), TLPH (period gap), LEEEF (period gap), SCYX (period gap), DERM (period gap), TSNDF (period gap), ASRT (no annual filing), IXHL (period gap), GSTK (no annual filing), PLNH (period gap), ITHUF (period gap), RMTI (period gap), CXXIF (period gap), AKBA (period gap), ADCT (period gap). Fiscal periods ending between 2024-09-30 and 2024-12-31. Every figure is one full fiscal year read from one annual filing (INCR: 20-F), reported in ILS. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INCR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INCR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.